Login to Your Account

Backloaded Deal Totals $380M

Clavis, Clovis Know it: CP-4126 May Be Better than Gemzar

By Cormac Sheridan

Wednesday, November 25, 2009
Shares in Clavis Pharma ASA soared on the Oslo Bors Tuesday, on news that it licensed its Phase II pancreatic cancer drug CP-4126 to Clovis Oncology Inc., for an up-front payment of $15 million, plus a potential $365 million in development, regulatory and sales-related milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription